Detalhe da pesquisa
1.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
N Engl J Med
; 389(23): 2162-2174, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38055253
2.
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer.
Br J Cancer
; 130(6): 941-950, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38245661
3.
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Br J Cancer
; 128(2): 255-265, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36482193
4.
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
Lancet
; 399(10324): 541-553, 2022 02 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35123694
5.
New therapies for clear cell ovarian carcinoma.
Int J Gynecol Cancer
; 33(3): 385-393, 2023 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36878571
6.
The peritoneal cancer index as a predictor of complete cytoreduction at primary and interval cytoreductive surgery in advanced ovarian cancer.
Int J Gynecol Cancer
; 33(11): 1757-1763, 2023 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37890875
7.
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
Int J Gynecol Cancer
; 33(9): 1331-1344, 2023 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37591609
8.
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
Int J Gynecol Cancer
; 33(8): 1253-1259, 2023 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37072323
9.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(7): 919-930, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35690073
10.
Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.
Gynecol Oncol
; 164(2): 325-332, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34952707
11.
PARP inhibitors in ovarian cancer: An overview of the practice-changing trials.
Genes Chromosomes Cancer
; 60(5): 385-397, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33382149
12.
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.
Lancet Oncol
; 22(5): 632-642, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33862001
13.
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 22(12): 1721-1731, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34715071
14.
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Lancet Oncol
; 22(7): 1034-1046, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34143970
15.
Translational genomics of ovarian clear cell carcinoma.
Semin Cancer Biol
; 61: 121-131, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31698086
16.
Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis.
Br J Cancer
; 124(6): 1130-1137, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33398064
17.
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
N Engl J Med
; 379(26): 2495-2505, 2018 12 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30345884
18.
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
Gynecol Oncol
; 163(1): 41-49, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34353615
19.
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
Gynecol Oncol
; 163(1): 72-78, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34412908
20.
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.
Future Oncol
; 17(29): 3781-3785, 2021 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34427115